New Antibacterial Agents
It is focused on the treatment of latent form of tuberculosis and its diagnosis. We built a Proteogenomic Data Bank of Mycobacteirum tuberculosis, identified a group of unpublished polypeptide sequences, specific for the latent stage of the disease and we have already began the development of an enzymatic test for identification of new drugs (small molecules) that inhibit the maintenance of the mycobacteria in the latent phase.
New molecular targets found by the Veritas team constitute mycobactericidal agents with a new mechanism of action for treatment of tuberculosis. These targets, that have unique characteristics, are already in the process of patent registration by Veritas for use as a screening test of new drugs against tuberculosis and use as a new therapy against this disease.
Platform and strategy
Veritas Life Sciences uses its substantial and unique technologic platform, named integrated-Proteomic Research System (i-PRS). This platform is constituted of modern proteomic technology, all integrated in a unique way in own protocols that allow the fast discovery of new compositions of biological materials with high biotechnological potential and commercial success. Our proven scientific expertise and business strategy guarantee us a neat path to advance in discovery, validation and commercialization of products in our R&D pipeline, decreasing significantly the time in development and increasing the chances of clinical success.
The Veritas products fit perfectly in the current tendency for globalization of R&D activities in biotechnology, that goes beyond the supplanted model of outsourcing of services with low value-added for CROs in less developed countries in exchange for a model more collaborative that represents a true alliance for research.
Differential Proteomics and Cellular Signaling
Alteration in the protein expression and the post-translational control are regulatory mechanisms present in all live cells. Post-translational modifications (PTM), for example, has the an important role in several biological processes, including parasite-host interaction regulation, oncogenesis and tumoral progression, as well as regulation of answers to stress in plants. The glocal and quantitative characterization of protein expression and the standards of post-translational modification in many stages of a tissue or organism (eg. Pathogenic state vs non-pathogenic; basal vc stress) is an important phase for the understanding of the complexity and interconnectivity of the regulatory biological nets.
The application of robust and quantitative proteomic platforms to analyze clinical samples, combined with laboratorial rigorous and standardized procedures in order to eliminate analytical variations, promise to accelerate the discovery of new targets and mechanisms to develop therapies and diagnostics.
The Biotechnological drugs are considered the future of the pharmaceutical industry. There are almost 1000 biological drugs and vaccines in development. The chemical drugs will continue to exist, but the biotechnological market will be bigger, as long as we advance for a personalized medicine direction. This clearly envolves the application of post-genomic technologies to discover thedifferent characteristics among the patient populations so that they can really benefit of personalized therapies. This new era of drugs will involve the idea to promote the right treatment for the patient in the right time.